The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy.
 
Michael White
No Relationships to Disclose
 
Ashish Damania
No Relationships to Disclose
 
Jumanah Alshenaifi
No Relationships to Disclose
 
Pranoti Sahasrabhojane
No Relationships to Disclose
 
Oliver Peacock
Travel, Accommodations, Expenses - American Society of Clinical Oncology
 
Jillian Losh
No Relationships to Disclose
 
Matthew C. Wong
No Relationships to Disclose
 
Zuzana Berkova
No Relationships to Disclose
 
Sa Thi Nguyen
No Relationships to Disclose
 
George J. Chang
Consulting or Advisory Role - Medicaroid
 
Jennifer Ann Wargo
Stock and Other Ownership Interests - Micronoma; OSE Immunotherapeutics
Honoraria - Bristol-Myers Squibb; DAVA Oncology; Exelixis; Gilead Sciences; Illumina; Imedex/HMP; MedImmune; Omniprex; Peerview; Physicans' Education Resource
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EverImmune; GlaxoSmithKline; Merck; Micronoma; Novartis; OSE Immunotherapeutics; Roche/Genentech
Patents, Royalties, Other Intellectual Property - PCT/US17/53.717
 
Nadim J. Ajami
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Y. Nancy You
No Relationships to Disclose